Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study

View ORCID ProfileCatherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
doi: https://doi.org/10.1101/2020.10.20.20215855
Catherine S. Storm
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catherine S. Storm
Demis A. Kia
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona Almramhi
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
2Department of Medical Laboratory Technology, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dilan Athauda
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Burgess
3MRC Biostatistics Unit, University of Cambridge, United Kingdom
4Cardiovascular Epidemiology Unit, University of Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Foltynie
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas W. Wood
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.wood@ucl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Exenatide is a glucagon-like peptide 1 receptor (GLP1R) agonist used in type 2 diabetes mellitus that has shown promise for Parkinson’s disease in a phase II clinical trial. Drugs with genetic evidence are more likely to be successful in clinical trials. In this study we investigated whether the genetic technique Mendelian randomization (MR) can “rediscover” the effects of exenatide on diabetes and weight, and predict its efficacy for Parkinson’s disease.

Methods We used genetic variants associated with increased expression of GLP1R in blood to proxy exenatide, as well as variants associated with expression of DPP4, TLR4 and 15 genes thought to act downstream of GLP1R or mimicking alternative actions of GLP-1 in blood and brain tissue. Using an MR approach, we predict the effect of exenatide on type 2 diabetes risk, body mass index (BMI), Parkinson’s disease risk and several Parkinson’s disease progression markers.

Results We found that genetically-raised GLP1R expression in blood was associated with lower BMI and possibly type 2 diabetes mellitus risk, but not Parkinson’s disease risk, age at onset or progression. Reduced DPP4 expression in brain tissue was significantly associated with increased Parkinson’s disease risk.

Conclusions We demonstrate the usefulness of MR using expression data in predicting the efficacy of a drug and exploring its mechanism of action. Our data suggest that GLP-1 mimetics like exenatide, if ultimately proven to be effective in Parkinson’s disease, will be through a mechanism that is independent of GLP1R in blood.

Competing Interest Statement

DA and TF are investigators on the Exenatide-PD and Exenatide-MSA trials. The other authors declare no competing interests. No funders had a role in the writing or decision to submit this manuscript for publication.

Funding Statement

No funders had a role in the design, data collection, analysis, interpretation, writing nor decision to submit this study. CSS is funded by Rosetrees Trust, John Black Charitable Foundation and the University College London MBPhD Programme. DAK is supported by an MBPhD Award from the International Journal of Experimental Pathology. MA is funded by the Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. NWW is a National Institute for Health Research senior investigator and receives support from the European Union Joint Programme Neurodegenerative Disease Research Medical Research Council Comprehensive Unbiased Risk factor Assessment for Genetics and Environment in Parkinsons disease. NWW receives support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. See supplementary notes for IPDGC Funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NA

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The GWAS data used by this study are publicly available as stated in the original publications. The supplementary information contains full results. We make our code openly available at https://github.com/catherinestorm/mr_exenatide.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
Catherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
medRxiv 2020.10.20.20215855; doi: https://doi.org/10.1101/2020.10.20.20215855
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
Catherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
medRxiv 2020.10.20.20215855; doi: https://doi.org/10.1101/2020.10.20.20215855

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10779)
  • Forensic Medicine (8)
  • Gastroenterology (583)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (864)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)